Company Description
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services.
The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services.
The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products.
This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies.
It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
| Country | United States |
| Founded | 1947 |
| IPO Date | Jun 23, 2000 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 21,800 |
| CEO | James Foster |
Contact Details
Address: 251 Ballardvale Street Wilmington, Massachusetts 01887 United States | |
| Phone | 781 222 6000 |
| Website | criver.com |
Stock Details
| Ticker Symbol | CRL |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001100682 |
| CUSIP Number | 159864107 |
| ISIN Number | US1598641074 |
| Employer ID | 06-1397316 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| James C. Foster J.D. | Chief Executive Officer, President and Chairman |
| Flavia H. Pease | Corporate Executive Vice President and Chief Financial Officer |
| Birgit Girshick | Corporate Executive Vice President and Chief Operating Officer |
| Joseph W. LaPlume J.D. | Corporate Executive Vice President of Corporate Development and Strategy |
| William D. Barbo | Corporate Executive Vice President of Community Relations |
| Michael Gunnar Knell | Corporate Senior Vice President and Chief Accounting Officer |
| Prof. Julie Frearson Ph.D. | Corporate Senior Vice President and Chief Scientific Officer |
| Mark Mintz | Corporate Senior Vice President and Chief Information Officer |
| Todd Spencer | Corporate Vice President of Investor Relations |
| Matthew L. Daniel J.D. | Corporate Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 144 | Filing |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 8, 2024 | 144 | Filing |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |